latest news releases from the newsroom
Discovery Laboratories, Inc.
Discovery Labs Restructures Loan Arrangement With Quintiles
WARRINGTON, Pa., Oct. 26, 2006 (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced the restructuring of its $8.5 million loan with PharmaBio Development, Inc., the strategic partnering group of Quintiles Transnational Corp. (Quintiles). Payment of the $8.5 million loan principal that was originally due December 31, 2006, has now been extended as a lump sum payment due on April 30, 2010.
REPORT FOR THE THIRD QUARTER AND THE FIRST NINE MONTHS OF 2006
* Operating profit excluding items affecting comparability amounted to SEK 32 M
* Profit before tax excluding items affecting comparability amounted to SEK 31
* Cash flow amounted to SEK 192 M (268).
* Net turnover amounted to SEK 10,195 M (8,690).
* Net profit amounted to SEK 39 M (120) and earnings per share to SEK 1.70
In a comment on the third-quarter results, Bilia’s Managing Director Jan
Telenor Satellite Services to be Acquired by Apax Partners
FORNEBU, Norway and PARIS, Oct. 26, 2006 (PRIMEZONE) -- On Wednesday October 25 2006, Telenor entered into a definitive agreement with Apax Partners France for the sale of Telenor Satellite Services (TSS) to funds managed by Apax Partners for a cash consideration of US$400 million (NOK 2,640 million). Since 2002 Telenor has defined Telenor Satellite Services as non-core business. Apax Partners intends to pursue the development of the company in Norway and abroad.
Hugin Ad Hoc Announcement According to Section 15 WpHG: Misc. Strategic Decisions: Epigenomics AG: Focus on Late Stage Product Development
BERLIN and SEATTLE, Oct. 26, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX), a German listed biotech company focusing on molecular diagnostics, today announced that it has completed an internal review of current operations in the context of its defined business strategy. To maximize its future growth potential and to enforce financial discipline, Epigenomics will focus its product development efforts entirely on later-stage programs in oncology, which are the company's key value drivers and greatest commercial opportunities. The partnership with Roche Diagnostics will not be affected by this measure. New clinical data from the colorectal and prostate cancer screening programs of this collaboration are expected in December as planned.